Description: Key Insights The projected fair value for Becton Dickinson is US$322 based on 2 Stage Free Cash Flow to Equity Becton...

Description: The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Becton, Dickinson and Company ( NYSE:BDX ) has announced that it will be increasing its dividend from last year's...

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™ Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive Conformité Européenne (CE) approval and is now available in select European countries.

Description: Ever wondered whether Becton Dickinson is a hidden gem or just another healthcare stalwart that’s not living up to its potential? You’re not alone. Today we’re unpacking its true value so you know exactly where it stands. After dipping 0.2% over the past week but rebounding for a 3.7% gain in the last month, the stock’s recent moves have caught investors’ attention. Its year-to-date return sits at -14.9%. This volatility follows industry-wide shifts in the healthcare sector and recent news...

Description: Becton Dickinson's consensus analyst price target has recently been revised downward, dropping from $206.58 to $201.49 in response to ongoing changes in the company's outlook. This adjustment reflects the evolving mix of optimism and caution among analysts, who are weighing the implications of updated forward guidance and sector challenges. Stay tuned to discover how you can monitor and interpret these shifts in the stock's narrative going forward. Stay updated as the Fair Value for Becton...

Description: HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.

Description: Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025.

Description: Hinde Group, an investment management company, has released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 14.37% (gross) and 13.93% (net) compared to 8.12% for the S&P 500 Total Return. The YTD return was 36.44% (gross) and 34.91% (Net) compared to 14.83% for the Index. The […]

Description: Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […]

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries.

Description: Becton Dickinson (BDX) shares have shown relatively little movement in the past week, edging up about 8%. Despite steady revenue and earnings growth over the past year, longer-term returns remain modest compared to market benchmarks. See our latest analysis for Becton Dickinson. BDX’s strong 7-day share price return of 8.6% stands out against a backdrop of long-term underperformance. Total shareholder returns remain in negative territory over the past one, three, and five years. While the...

Description: In recent days, Becton Dickinson (BD) introduced the PureWick™ Portable Collection System, an at-home, battery-powered urine management device for wheelchair users, and saw Duncan Regional Hospital become the first U.S. facility to implement BD Alaris™ EMR Infusion Interoperability with the MEDITECH electronic health record system. These developments expand BD’s reach into direct-to-consumer care and strengthen its market-leading interoperability capabilities in infusion safety, positioning...

Description: Expanded Partnership Will Increase Access to Diabetes Care for Communities Across the U.S. and Globally SANTA BARBARA, CA / ACCESS Newswire / November 14, 2025 / On World Diabetes Day, embecta Corp. (NASDAQ:EMBC), the largest manufacturer of insulin ...

Description: Exploring the Latest 13F Filing for Q3 2025

Description: BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Description: Although Becton, Dickinson and Company has underperformed the broader market over the past year, Wall Street analysts maintain a measured optimism about the company’s long-term outlook.

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Duncan Regional Hospital ("DRH Health") has become the first hospital in the United States to implement BD Alaris™ EMR (Electronic Medical Record) Interoperability with the MEDITECH electronic health record (EHR), marking a significant advancement in patient safety, workflow efficiency and clinician support.

Description: Soft earnings didn't appear to concern Becton, Dickinson and Company's ( NYSE:BDX ) shareholders over the last week. We...

Description: BD’s third quarter results were broadly in line with Wall Street expectations, reflecting resilience across most of its product portfolio even as certain market headwinds emerged. Management credited strong demand in Interventional, Biologics, and Advanced Patient Monitoring segments for supporting organic growth, while acknowledging that vaccine demand and subdued research funding weighed on parts of the business. CEO Thomas Polen highlighted the sequential acceleration in organic growth and po

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: The board of Becton, Dickinson and Company ( NYSE:BDX ) has announced that the dividend on 31st of December will be...

Description: Becton Dickinson’s stock narrative has shifted slightly, with the Fair Value Estimate declining modestly from $208 to approximately $206.58 as analysts take a more cautious stance on upcoming earnings. In addition, the discount rate has risen from 8.17% to 8.57%, suggesting the market is now pricing in a higher level of risk. Stay tuned to discover what is driving these changes and how you can continue tracking this evolving story. Stay updated as the Fair Value for Becton Dickinson shifts by...

Description: Quite a few insiders have dramatically grown their holdings in Becton, Dickinson and Company ( NYSE:BDX ) over the past...

Description: After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.

Description: Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates.

Description: Dividend Kings are stocks that’ve had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT), Becton Dickinson (NYSE:BDX), and Hormel Foods (NYSE:HRL). That is an exceptional feat that the vast majority of stocks in the market cannot match. For a business to pay rising dividends to its shareholders for half ... 3 Undervalued Dividend Kings to Buy on the Dip Right Now

Description: Becton Dickinson & Co (BDX) reports robust Q4 performance with a 7% revenue increase, strategic share buybacks, and a focus on innovation to drive future growth.

Description: BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.

Description: Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Becton Dickinson (BDX) delivered earnings and revenue surprises of +1.02% and +0.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: US equity markets were mostly pointing higher before Thursday's opening bell as investors assess the

Description: Investing.com -- Becton Dickinson posted fourth-quarter earnings that came in slightly above expectations and offered guidance that also beat forecasts.

Description: Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates.

Description: FRANKLIN LAKES, N.J. (AP) — Becton Dickinson and Co. (BDX) on Thursday reported fiscal fourth-quarter profit of $493 million. The Franklin Lakes, New Jersey-based company said it had profit of $1.72 per share. Earnings, adjusted for one-time gains and costs, were $3.96 per share.

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 fourth quarter and full year, which ended September 30, 2025.

Description: The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share.

Description: McKesson (MCK) delivered earnings and revenue surprises of +10.54% and -1.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be reporting results this Thursday before market hours. Here’s what to expect.

Description: The global Foley catheters market is anticipated to grow to USD 1.20 billion by 2030, from USD 931.0 million in 2025, at a CAGR of 5.3%. This growth is fueled by increasing urological disorders, rising surgical volumes, and improved healthcare infrastructure in emerging economies. A surge in demand is noted for 5 mL balloons due to their comfort in catheterization. While latex catheters dominate due to cost-effectiveness, Europe's advanced healthcare drives the largest regional market share. Top

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD).

Description: The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com

Description: US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)

Description: In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Description: The benchmark US stock measures were tracking in the green before the opening bell Monday as traders

Description: BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System.

Description: Merit Medical (MMSI) delivered earnings and revenue surprises of +12.20% and +3.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Becton Dickinson (NYSE:BDX) has had a rough week with its share price down 3.5%. It is possible that the markets have...

Description: On October 10, 2025, Ulta Beauty's Board of Directors appointed Christopher DelOrefice as Chief Financial Officer, effective December 5, 2025, following an extensive leadership career at Becton Dickinson & Company and Johnson & Johnson. The appointment comes as Ulta Beauty prepares for its third-quarter results amidst analyst expectations for a double-digit earnings drop and heightened margin pressures this year. We'll explore how investor focus on Ulta Beauty's upcoming earnings amid margin...

Description: Over the past six months, BD’s stock price fell to $181.01. Shareholders have lost 12.6% of their capital, which is disappointing considering the S&P 500 has climbed by 23.8%. This may have investors wondering how to approach the situation.

Description: Dividend Aristocrats are some of the best stocks to buy when they go on sale, as they’re backed by companies on a solid footing. These companies have raised the dividends on their businesses each year for over a quarter of a century and are continuously cranking out cash for their shareholders. This characteristic lets them ... 3 Beaten-Down Dividend Aristocrats Ready to Rebound by 100%

Description: Med-tech veteran Robert Kline has joined the Board of Directors at PainTEQ, a strategic move to capitalize on his commercialization and growth expertise as the company redefines interventional spine care.

Description: Thinking about what to do with your Becton Dickinson shares, or considering jumping in? You are definitely not alone. With a closing price of $185.83 and a rollercoaster year behind it, there is plenty for investors to unpack. The stock has dipped by 18.0% year-to-date and is down 20.3% over the past twelve months. Even over three and five years, the returns have been negative, which naturally raises some eyebrows about long-term prospects and value. What is driving these moves? While there...

Description: Becton Dickinson (BDX) shares have moved in a fairly narrow range this past week, with little in the way of major news or company updates to spark momentum. Investors may be reevaluating the stock's recent returns and valuation. See our latest analysis for Becton Dickinson. This recent stretch of subdued trading follows a year where Becton Dickinson’s share price has slid, with a year-to-date price return of -17.64% and a total shareholder return over the past year of -20.19%. The longer-term...

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Becton, Dickinson & Company is gearing up to announce its Q4 results next month, with analysts calling for a slight dip in profits.

Description: Fiduciary Management Inc. (FMI), an independent money management firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Stock markets rallied in the third quarter, with the Russell 2000, S&P 500, MSCI EAFE (Local/USD), and MSCI World Indices gaining 12.39%, 8.12%, 5.38%/4.77%, and 7.27% respectively. The performance was driven by […]

Description: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System.

Description: BD's new AI-driven Incada Platform and upgraded Pyxis Pro system unite connected care, driving its digital healthcare edge.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Disney names an insider as CFO of Disney Experiences, Ulta Beauty appoints a new finance chief and Liquid Death hires a former PepsiCo exec as chief financial officer.

Description: Chris Lialios will continue as interim CFO until DelOrefice assumes the position in December 2025